t6128 (TargetMol)
Structured Review
T6128, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 6 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pha665752/PHA665752/pmc12718461-52-4-2
Average 94 stars, based on 6 article reviews
Images
Related Articles
other:Article Title: HHLA2 activates c-Met and identifies patients for targeted therapy in hepatocellular carcinoma Article Snippet: 4 Antibodies and Drugs Suppliers Catalog Number Clonality Host Species Concentrations/ dilutions HHLA2/B7-H7 CST 52200S Monoclonal Rabbit WB 1:1000 HHLA2 Abcam ab214327 Polyclona l Rabbit IHC 1:100 c-Met Protein tech 25869-1-AP Polyclona l Rabbit WB 1:1000 IHC 1:500 p-Met(Tyr1234/1235) CST 3077S Monoclonal Rabbit WB 1:1000 IHC 1:100 HA-Tag CST 3724S Monoclonal Rabbit WB 1:1000 IHC 1:800 GAPDH Protein tech HRP-60004 Monoclonal Mouse WB 1:10000 VEGFA Protein tech 19003-1-AP Polyclona l Rabbit WB 1:2000 p44/42 MAPK (Erk1/2) CST 4695S Monoclonal Rabbit WB 1:1000 p-p44/42 MAPK(Erk1/2) CST 4370S Monoclonal Rabbit WB 1:2000 MMP9 (N-Termina l) Protein tech 10375-2-AP Polyclona l Rabbit WB 1:500 ICAM-1 Protein tech 10831-1-AP Polyclona l Rabbit WB 1:5000 HGF β CST 52445t Monoclonal Rabbit WB 1:1000 human N-cadher in Protein tech 22018-1-AP Polyclona l Rabbit WB 1:2000 E-cadher in Protein tech 60335-1-Ig Monoclonal Mouse WB 1:2000 Myc CST 2276S Monoclonal Mouse IHC 1:500 CD34 ABclonal A19015 Monoclonal Rabbit IHC 1:100 Article Title: Protocol for high-content drug screening using tumor organoids on a 384-pillar plate platform Article Snippet: Article Title: Targeting of a novel interplay between MET tyrosine kinase and NRF2 enhances sensitivity to Paclitaxel in triple negative breast cancer Article Snippet: Primary antibodies are used as follows: anti-NRF2 (D1Z9C) (12721; Cell Signalling Technology), anti-NRF2 (EP1808Y) (ab-62352; Abcam), anti-phospho-SRC (Tyr416) (2101; Cell Signalling Technology), anti-SRC (2108; Cell Signalling Technology), anti-phospho-MET (Tyr1234/35) (3126; Cell Signalling Technology), anti-MET (3127; Cell Signalling Technology), anti-heme oxygenase 1 (A-3) (sc-136960; Santa Cruz Biotechnology), anti-phospho-histone H2AX (Ser139) (9718; Cell Signalling Technology), anti-KEAP1 (G-2) (sc-365626; Santa Cruz Biotechnology), anti-KEAP1 (F-10) (sc-514914; Santa Cruz Biotechnology), anti-p62 (SQSTM1) (PM045; MBL International), anti-phospho-p62 (SQSTM1) (Ser349) (PM074; MBL International), anti-phospho-EGFR (Tyr1068) (3777; Cell Signalling Technology), anti-EGFR (LA22) (05–104, Sigma-Aldrich), anti-8-OHdG (sc-66036, Santa Cruz Biotechnology), anti-vinculin (13901; Cell Signalling Technology), anti-lamin A/C (sc-376248; Santa Cruz Biotechnology), anti-GAPDH (sc-47724; Santa Cruz Biotechnology), anti-β-Actin (3700, Cell Signalling Technology); Article Title: A functional genomics-pharmacotranscriptomics framework identifies host-directed anti-influenza agents Article Snippet: Fractionation:Article Title: Targeting of a novel interplay between MET tyrosine kinase and NRF2 enhances sensitivity to Paclitaxel in triple negative breast cancer. Article Snippet: .. Primary antibodies used are as follows: anti-NRF2 (D1Z9C) (12721; Cell Signalling Technology), anti-NRF2 (EP1808Y) (ab-62352; Abcam), anti-phospho-SRC (Tyr416) (2101; Cell Signalling Technology), anti-SRC (2108; Cell Signalling Technology), anti-phospho-MET (Tyr1234/35) (3126; Cell Signalling Technology), anti-MET (3127; Cell Signalling Technology), anti-heme oxygenase 1 (A-3) (sc-136960; Santa Cruz Biotechnology), anti-phospho-histone H2AX (Ser139) (9718; Cell Signalling Technology), anti-KEAP1 (G-2) (sc-365626; Santa Cruz Biotechnology), anti-KEAP1 (F10) (sc-514914; Santa Cruz Biotechnology), anti-p62 (SQSTM1) (PM045; MBL International), anti- AR TIC LE IN PR ES S phospho-p62 (SQSTM1) (Ser349) (PM074; MBL International), anti-phospho-EGFR (Tyr1068) (3777; Cell Signalling Technology), anti-EGFR (LA22) (05-104, Sigma-Aldrich), anti-8-OHdG (sc66036, Santa Cruz Biotechnology), anti-vinculin (13901; Cell Signalling Technology), anti-lamin A/C (sc-376248; Santa Cruz Biotechnology), anti-GAPDH (sc-47724; Santa Cruz Biotechnology), anti-β-Actin (3700, Cell Signalling Technology); Western Blot:Article Title: Targeting of a novel interplay between MET tyrosine kinase and NRF2 enhances sensitivity to Paclitaxel in triple negative breast cancer. Article Snippet: .. Primary antibodies used are as follows: anti-NRF2 (D1Z9C) (12721; Cell Signalling Technology), anti-NRF2 (EP1808Y) (ab-62352; Abcam), anti-phospho-SRC (Tyr416) (2101; Cell Signalling Technology), anti-SRC (2108; Cell Signalling Technology), anti-phospho-MET (Tyr1234/35) (3126; Cell Signalling Technology), anti-MET (3127; Cell Signalling Technology), anti-heme oxygenase 1 (A-3) (sc-136960; Santa Cruz Biotechnology), anti-phospho-histone H2AX (Ser139) (9718; Cell Signalling Technology), anti-KEAP1 (G-2) (sc-365626; Santa Cruz Biotechnology), anti-KEAP1 (F10) (sc-514914; Santa Cruz Biotechnology), anti-p62 (SQSTM1) (PM045; MBL International), anti- AR TIC LE IN PR ES S phospho-p62 (SQSTM1) (Ser349) (PM074; MBL International), anti-phospho-EGFR (Tyr1068) (3777; Cell Signalling Technology), anti-EGFR (LA22) (05-104, Sigma-Aldrich), anti-8-OHdG (sc66036, Santa Cruz Biotechnology), anti-vinculin (13901; Cell Signalling Technology), anti-lamin A/C (sc-376248; Santa Cruz Biotechnology), anti-GAPDH (sc-47724; Santa Cruz Biotechnology), anti-β-Actin (3700, Cell Signalling Technology); Protease Inhibitor:Article Title: Targeting of a novel interplay between MET tyrosine kinase and NRF2 enhances sensitivity to Paclitaxel in triple negative breast cancer. Article Snippet: .. Primary antibodies used are as follows: anti-NRF2 (D1Z9C) (12721; Cell Signalling Technology), anti-NRF2 (EP1808Y) (ab-62352; Abcam), anti-phospho-SRC (Tyr416) (2101; Cell Signalling Technology), anti-SRC (2108; Cell Signalling Technology), anti-phospho-MET (Tyr1234/35) (3126; Cell Signalling Technology), anti-MET (3127; Cell Signalling Technology), anti-heme oxygenase 1 (A-3) (sc-136960; Santa Cruz Biotechnology), anti-phospho-histone H2AX (Ser139) (9718; Cell Signalling Technology), anti-KEAP1 (G-2) (sc-365626; Santa Cruz Biotechnology), anti-KEAP1 (F10) (sc-514914; Santa Cruz Biotechnology), anti-p62 (SQSTM1) (PM045; MBL International), anti- AR TIC LE IN PR ES S phospho-p62 (SQSTM1) (Ser349) (PM074; MBL International), anti-phospho-EGFR (Tyr1068) (3777; Cell Signalling Technology), anti-EGFR (LA22) (05-104, Sigma-Aldrich), anti-8-OHdG (sc66036, Santa Cruz Biotechnology), anti-vinculin (13901; Cell Signalling Technology), anti-lamin A/C (sc-376248; Santa Cruz Biotechnology), anti-GAPDH (sc-47724; Santa Cruz Biotechnology), anti-β-Actin (3700, Cell Signalling Technology); |

